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Synopsis:  
Teams of investigators from around the world are investigating the potential of selective 
omission of breast cancer surgery following neoadjuvant systemic therapy. Clinical trials 
are described and remaining challenges in the field discussed.  
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Abstract  
With current advances in neoadjuvant systemic therapy (NST) and improved breast 
imaging, the potential of nonoperative therapy for invasive breast cancer has emerged 
as a viable option when utilizing meticulous image guided percutaneous biopsy to 
document pathologic complete response.  Feasibility clinical trials utilizing this approach 
are being performed by teams of investigators from single and multi-center/cooperative 
groups around the world.  Imaging alone after NST lacks sufficient sensitivity and 
specificity in predicting pCR and therefore can’t be utilized for clinical selection of 
patients for omission of surgery. Imaging with adequate sampling after NST of the 
residual lesions (or around the remaining clip if a complete radiologic response occurs) 
appears to be essential in selecting patients with pCR to lower the false-negative rates 
based on initial reported feasibility studies to identify pCR without surgery that range 
from 5% to 49%.   In this manuscript recently completed, ongoing, and planned clinical 
feasibility trials and a new omission of surgery trial are described. Drastic rethinking of 
all diagnostic and therapeutic management strategies that are ordinarily utilized for 
patients who receive standard breast cancer surgery is required.  A roadmap of 
essential questions and issues that will have to be resolved as the field of nonoperative 
breast cancer management advances is described in detail.   
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INTRODUCTION 
Avoidance of surgery in select breast cancer patients with excellent 
documented pathologic response with neoadjuvant systemic therapy (NST) by 
percutaneous means, if proved to be safe and effective, has the potential of 
decreasing post-surgical complications, improving quality-of-life, and decreasing 
health care costs.1-5  Historically, attempts of omission of surgery in breast cancer 
patients treated with NST resulted in high rates of local-regional recurrence.2  
Most of these initial studies had suboptimal methodologies including use of only 
physical examination to determine clinical response, lack of selection of patients 
by disease subtype, and/or lack of utilization of enhanced image-guided biopsy to 
assess for pathologic response.2,4,6 The main impediment to potential omission of 
surgery for breast cancer has been the fact that standard breast imaging 
methods cannot accurately predict the status of the absence of residual disease 
after NST.2,3,7-9  In this manuscript, recently completed, ongoing, and planned 
clinical feasibility and omission of surgery after NST trials are described (Table 1) 
in order to summarize the state of the science of the field and develop a roadmap 
of essential questions to be addressed. 
 
German Breast Group and the University of Heidelberg 
 From 2009-2013, 164 patients with histologically confirmed, non-metastatic, 
invasive breast cancer showing a clinical complete response (cCR) after NST were 
enrolled in this multicenter study.4 Core cut (CC) biopsy was performed on 116 patients, 
and vacuum-assisted core biopsy (VACB) on 46 patients. Biopsies were guided by 
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ultrasound in 144 cases and by mammography in 20 cases. The main study endpoint 
was the false negative rate (FNR). Overall analysis calculated a FNR of 49.3% (95% CI: 
(40.4%; 58.2%). However, there was no false negative result in the mammographic 
guided VACB (negative predictive value (NPV) 100%; FNR 0%). Overall, the study 
hypothesized a high potential for VACB techniques. However, insufficient diagnostic 
accuracy was attributed to a lack of evaluation of the representativeness of the biopsy 
as well as to the use of non-standardized biopsy and pathology procedures. 
In order to better assess the representativeness of the biopsy, three different 
evaluation methods were compared at the University of Heidelberg: the subjective 
evaluation of the physician taking the biopsy, specimen radiography, and 
histopathological evaluation of the biopsy specimen.5 Out of 87 screened patients in 
2014-15, 50 patients with complete or partial response were assigned to the study as 
partial responders by imaging may also result in pCR. The main study endpoint was the 
FNR comparing the histopathological evaluation of the biopsy with the surgical 
specimen. Analysis of the whole cohort yielded a FNR of 25.9% (95% CI 13.8-38.0). 
Given a pathologically representative VACB sample (n=38) the FNR 4.8% (95% CI 0.0-
11.6), which demonstrates the high diagnostic potential of a VACB when combined with 
careful histologic review. Toward this end, it is of interest to determine how often 
residual histologic changes are and are not seen among cases with a pCR.  However, 
the crucial challenge remains identifying reliable techniques to prevent sampling errors.  
Based on these results, the investigators designed a multicenter trial (RESPONDER) 
which will commence this year and will enroll 600 patients with breast cancer showing at 
8 
 
least a partial response with NST to address imaging of the target lesion (tumor and or 
clip) and biopsy and standardizing pathologic processing (Table 1).10  
 
Netherlands Cancer Institute Amsterdam 
The MICRA trial [(Minimally Invasive Complete Response Assessment of the 
breast after neoadjuvant systemic treatment (trialregister.nl – NTR6120)] is a 
prospective multi-center observational cohort study.11  In this trial that is currently 
accruing, investigators at the Netherlands Cancer Institute are assessing the value of 
biopsies of the breast in determining pathologic response to NST in breast cancer 
patients. The study population consists of 525 patients with invasive breast cancer 
treated with NST adapted to the different subtypes (all subtypes are included); patients 
with proven DCIS are excluded. Group A consists of 375 women with radiologic 
complete response (rCR) on contrast enhanced-magnetic response imaging (CE-MRI). 
Group B consists of 150 patients with partial response (0.1 – 2.0 cm contrast 
enhancement and/or with ≥30% decrease in tumor size according to the RECIST 
criteria) on CE-MRI. 
In all patients receiving NST, a marker is placed in the center of the original 
tumor area in the breast. After NST and CE-MRI, 8 ultrasound-guided 14 gauge core 
biopsies are obtained in the region surrounding the marker (4 biopsies central near the 
marker within 0.5 cm and 4 biopsies 1.0 to 1.5 cm from the marker), while the patient is 
under general anesthesia. Immediately thereafter, breast surgery is performed.  The 
pathology results of biopsies and surgical specimens are compared.  The primary 
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endpoint is a specificity of >92% (meaning the proportion of patients with residual 
disease in the surgical specimen that is correctly confirmed by biopsy). FNR will also be 
calculated.  
In order to selectively eliminate surgery of the axilla we developed the MARI 
procedure (Marking of the Axillary node with a Radioactive Iodine seed).12,13 By 
combining the MARI procedure with PET/CT staging of the axilla prior to NST we are 
now able to omit axillary nodal dissection in up to 80 % of our N1-2 and 3 patients.14  In 
line with the MICRA trial, we designed the MACRA trial (scheduled to start) to further 
deescalate surgery of the axilla with the intention of identifying pCR of the axilla by 
ultrasound guided FNA and/or biopsy of the MARI – node instead of removal of this 
node.  
University of Birmingham, United Kingdom 
NOSTRA PRELIM and NOSTRA Feasibility Trial (NO Surgery TRiAl)   
NOSTRA PRELIM describes preliminary work undertaken in a diverse patient group 
undergoing NST at the University of Birmingham to assess the acceptability and 
feasibility of post-treatment tumor bed biopsy and to inform the methodology to utilize 
for the biopsy component in the planned NOSTRA feasibility trial.15  Patients were 
eligible if the tumor could be seen on US, was ≥ 1 cm, and had any receptor type.  US 
was utilized at the end of therapy to biopsy the tumor region utilizing 4 to 6 biopsies in a 
total of 22 patients.  The size of the initial cancers measured 1.5 cm to 6.1 cm. Two 
patients had a pCR, 7 patients had a partial pathologic response, 11 patients had stable 
disease, and 2 patients had not had surgery.  There were 4 false-negative events which 
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resulted in correctly identifying disease in 82% of participants (18 patients).  It should be 
noted that mammography and stereotactic biopsy were not utilized to assess concurrent 
malignant microcalcifications. The investigators of this preliminary investigation 
concluded that residual disease can be missed if there is inadequate sampling and 
requires that a minimum of 6 biopsies will be needed in the NOSTRA Feasibility Trial.  
There will be a total of 150 participants with triple-negative (TN) or HER2-positive (who 
have tumor size greater than 1 cm and or node positive) invasive breast cancer 
receiving NST in the NOSTRA feasibility study.  Following NST, a minimum of six 
ultrasound-guided biopsies will be obtained to determine the FNR following standard 
surgery with an endpoint of FNR of < 10% in order to proceed to a definitive no surgery 
planned trial.  
NRG Oncology Group (formerly the National Surgical Adjuvant Breast and 
Bowel Project [NSABP], Radiation Therapy Oncology Group [RTOG], and 
Gynecologic Oncology Group [GOG]) 
NRG BR005: Pilot trial evaluating core biopsy in patients with complete radiologic 
response after neoadjuvant chemotherapy 
NRG BR005 is a multicenter cooperative group approved study that will evaluate 
the accuracy of image-guided biopsy of the residual tumor bed to predict pCR in 175 
operable breast cancer patients undergoing NST who have a complete clinical and near 
complete radiological response. This study will evaluate the NPV and FNR of post-NST 
tumor bed biopsy as a prelude to a large multicenter study evaluating the omission of 
surgery for locoregional management with radiation alone in patients with excellent 
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response to NST. Patients with operable breast cancer of all types except lobular 
carcinoma and who have evidence of clinical complete response after neoadjuvant 
therapy will undergo trimodality imaging (mammogram, ultrasound and MRI) to assess 
eligibility. Patients who have a complete or near-complete imaging response, and who 
are candidates for breast conserving surgery will undergo VACB with removal of 6 to 8 
11G biopsy core samples along with clip removal and replacement at the time of the 
biopsy.  Axillary surgery and radiotherapy will be performed as per local standard of 
care. Secondary objectives include an evaluation of residual cancer burden, the number 
of cores performed and the NPV of a trimodality imaging algorithm. The hypothesis 
being tested is that the NPV will be at least 90% and the FNR < 10% in order to proceed 
to the phase III study of surgery avoidance.  An interim analysis of the first 27 patients 
with detectable residual tumor at final pathology (approximately the first 135 patients in 
the entire study) will be performed so as to determine if the study should continue. If this 
threshold is not met (NPV<90%) than this approach would be deemed insufficient to 
identify the cohort that could safely move on to the randomized controlled trial of 
surgery vs no surgery. 
MD Anderson Cancer Center 
Feasibility trial for identification of patients for eliminating breast cancer surgery 
following neoadjuvant systemic therapy  
The accuracy of fine-needle aspiration (FNA) and vacuum-assisted core biopsy (VACB) 
was determined in assessing pCR (no invasive or in situ disease) following NST.16 The 
sample size of 40 was determined to provide sufficient information to characterize the 
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diagnostic properties of VACB assuming an estimated 90% sensitivity and specificity for 
VACB after NST. Forty patients with clinical T1-3N0-3 limited to TN or HER2-positive 
breast cancer receiving NST were enrolled. The biopsy technique utilized was decided 
by the radiologist based on the best imaging modality for VACB based on the patient’s 
final imaging results and performed in the breast imaging suite. Findings were 
compared with findings on pathologic evaluation to determine the performance of 
image-guided biopsy in predicting residual breast disease after NST. Nineteen patients 
(47.5%) had a breast pCR and the axillary node pathologic status was concordant with 
the breast pathologic response in 98% of cases. Combined FNA/VACB demonstrated 
an accuracy of 98% (95% CI, 87%-100%), false-negative rate of 5% (95% CI, 0%-24%), 
and negative predictive value of 95% (95% CI, 75%-100%) in predicting residual breast 
cancer. There were a number of other findings in this study that deserve mention: 1) the 
median number of 9G image guided VACB were 12 among trial participants and the 
false-negative results occurred in the 2 cases where the number of cores were at or 
below 6, 2) median initial tumor size was 3 cm and final median size 1.1 cm, 3) breast 
imaging consisted of only digital mammography and ultrasound (no MRI required), 4) a 
radiologic complete response was seen in 25% of participants and in these patients a 
breast pCR occurred in 80% while a partial radiologic response occurred in 75% of 
participants and in these patients a breast pCR occurred in 37%.   
Management of the axilla among patients with a breast pCR identified by image guided 
biopsy after NST 
Although we demonstrated that the pathologic status of the axilla correlated and was 
concordant with the pathologic response in the breast after NST in 98% of cases, it was 
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of interest for our group to analyze this scenario in a larger cohort of patients at MD 
Anderson.17   Data from a recent retrospective study at our institution showed that 
breast pCR after NST correlated with nodal pCR after NST. This study included 290 
patients with TN/HER2-positive breast cancer with T1-2N0 disease and normal findings 
on nodal sonography at diagnosis. Of the 116 patients who had a pCR in the breast 
after NST, none (0%) had evidence of axillary lymph node metastases after NST. 
Among 237 patients with FNA/core biopsy-documented N1 disease, 89.6% of patients 
with a breast pCR after NST had no evidence of axillary metastases, 57.5% of patients 
without a breast pCR had residual axillary metastases.  
Eliminating breast cancer surgery in exceptional responders with neoadjuvant systemic 
therapy18 
Based on the results of the clinical feasibility trial at MD Anderson and the analysis 
related to nodal status among patients with a breast pCR, the clinical trial for omission 
of breast surgery has begun accrual.18 This single center phase 2 study in which 50 
participants with TN/HER2-positive breast cancer presenting with tumors less than 5 cm 
with or without N1 nodal metastases are eligible following standard NST regimens 
(Figure).  VACB will occur in responding patients provided that the tumor region is ≤ 2 
cm and/or greater than 90% of the residual lesion is sampled with the minimum of 12 
9G VACBs.  Patients without residual disease move on to standard whole breast 
radiotherapy without breast surgery (Figure).  Patients with initial ultrasound biopsy 
confirmed N1 disease are also eligible to participate in the study if VACB does not 
demonstrate residual breast disease as approximately 90% of these patients will also 
have a pCR in the lymph nodes.  However, these patients will require targeted axillary 
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dissection to confirm no residual disease prior to radiotherapy.19 The primary endpoint 
for the trial is five year local-regional recurrence and will utilize continuous monitoring 
with ipsilateral mammography and ultrasonography every 6 months such that early 
stopping rules are in place.  
Summary and Conclusions 
Tumor response to NST is well-known to significantly impact local regional 
therapy by downsizing disease which facilitates breast conserving surgery and 
increases eligibility for limited axillary surgery in selected patients.13,19,20 The omission of 
surgery in the setting of exceptional response to NST, the ultimate breast conserving 
strategy, is being actively studied.  The results of the clinical trials described in this 
manuscript have identified essential elements that are needed to ensure accuracy and 
safety in selecting patients for avoidance of surgery. These include the use of high 
quality image guidance of residual lesions after NST with an adequate sampling of 
residual imaging abnormalities. This will require limiting patients for this potential 
approach with either a complete radiologic response or near complete radiologic 
response for adequate pathologic assessment for residual disease. The question of 
which imaging modality or combination of breast imaging combined with VACB that will 
best ensure the lowest false-negative rates and highest negative predictive values 
remains to be determined and will be answered with the ongoing trials as described. 
Patients with the highest chance of disease eradication include those with triple 
negative and HER2-positive subtypes (40-60%) although patients with ER-positive 
disease may also become eligible (5-20%) for this approach.   
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The concept of nonoperative therapy of breast cancer utilizing state-of-the-art 
image guided biopsy to appropriately select patients for avoidance of surgery is a new 
arena in breast cancer management and thus there are many questions that need to be 
addressed.  With any new paradigm consideration it will sometimes require drastic 
rethinking of our standard diagnostic and therapeutic management strategies. Table 2 
provides a roadmap of essential questions and issues that need to be resolved as the 
field of nonoperative breast cancer management advances.  In conclusion, safety of this 
approach and methods to ensure this are of prime importance.  
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Table 1. Completed, Ongoing, and Planned Clinical Feasibility Trials Utilizing Percutaneous Biopsy after 
Neoadjuvant Therapy to Select Patients for Omission of Breast Cancer Surgery 
 
 
Status Group/Author-PI Eligibility 
Criteria/Lesion Size 
Criteria   
Type of Biopsy   # Patients Study unique 
characteristics 
Performance 
Results 
 
Completed 
Trials 
 
MD Anderson 
Cancer Center/ 
Kuerer et al.
16
 
All lesions less than 5 
cm on imaging after 
NST; included only 
TN and HER2-
amplified cases 
VACB and FNA; 
median number 
sampled 12 using 9G 
under radiologist 
defined image 
guidance (63% by 
stereotactic and 37% 
by ultrasound) 
40 Meticulous image 
guided sampling in 
radiology suite 
 
Subtype specific 
with highest 
probability of pCR 
(no invasive and in 
situ) 
Accuracy=98%; 
FNR=5%; 
NPV=95% 
German Breast 
Group/ Heil et al.
4,6
 
Invasive breast 
cancer patients; non-
metastatic; with 
clinical imaging after 
neoadjuvant 
chemotherapy/No 
lesion size criteria 
Core cut (CC) and 
vacuum-assisted 
biopsy (VACB) 
164 (111 
with CC and 
46 with 
VACB) 
Explorative 
comparison of 
different 
techniques: CC and 
VACB, ultrasound 
and mammographic 
guidance 
Entire cohort 
(n=164): NPV 
71.3%;  FNR 
49.3%;  
 
Mammographic 
guided VACB 
(n=16): NPV 100%; 
FNR 0% 
University of 
Heidelberg/Heil et 
al.
5
 
Histologically 
confirmed, unilateral 
breast cancer; clinical 
partial or complete 
response to NST; 
target lesion visible 
by ultrasound/No 
lesion size criteria 
Ultrasound-guided 
VACB 
50 Explorative 
comparison of three 
evaluation methods 
of biopsy specimen 
pathologic 
representativeness 
Entire cohort 
(n=50): NPV 
76.7%;  FNR 
25.9%;  
 
Histopathological 
evaluation of 
representativeness 
(n=38): NPV 
94.4%; FNR 4.8% 
 
University of  
Birmingham/  
Rea-Francis et al./ 
Invasive breast 
cancer with any 
receptor subtype 
Ultrasound guided core 
biopsy; 4 to 6; 
mammography and 
22 Designed to inform 
biopsy protocol for 
larger study 
Number of patients 
with a false-
negative result (4 of 
17 
 
NOSTRA 
PRELIM
15
 
receiving NST/No 
lesion size criteria 
stereotactic biopsy not 
utilized for malignant 
calcifications 
18 total patients)  
Ongoing 
Trials 
MD Anderson 
Cancer Center/ 
Kuerer et al.
18
 
TN or HER2-positive 
initial imaging size < 
5 cm and final size < 
2 cm and or > 90% of 
lesion sampled after 
NST; N0 or biopsy 
confirmed N1 with < 
4 abnormal nodes on 
initial ultrasound 
Minimum of 12 9G 
VACB; image guidance 
method dependent on 
radiologist decision 
50 No breast surgery 
treatment trial  
Primary endpoint is 
local recurrence 
with continuous 
monitoring and 
early stopping 
rules; secondary 
endpoints listed in 
Figure 
Netherlands 
Cancer Institute 
MICRA Trial/ 
MACRA Trial 
Vrancken-Peeters 
et al.
11
 
Invasive breast 
cancer patients; non-
metastatic; with 
radiologic partial or 
complete response 
on CE-MRI after 
NST/No lesion size 
criteria 
Ultrasound guided 14G 
biopsies targeted 
around pre-NST 
placed marker (4 
central; 4 peripheral)  
 
 
525 (150 
with partial 
radiologic 
response on 
CE-MRI and 
375 with 
complete 
radiologic 
response on 
CE-MRI) 
All breast cancer 
subtypes; 
Response 
monitoring with CE-
MRI 
 
Primary endpoint is 
a specificity of 
>92% (proportion of 
patients with 
residual disease in 
the surgical 
specimen that is 
also confirmed by 
biopsy).  
In addition, FNR, 
will be calculated.  
University of 
Heidelberg/ 
RESPONDER Trial 
Heil et al.
10
 
Invasive breast 
cancer after NST;  
clinical partial or 
complete response; 
target lesion visible 
on ultrasound or 
mammography/No 
lesion size criteria 
Ultrasound or 
mammographic guided 
VABC 
600 Confirmative 
analysis to identify 
a pCR using VACB 
 
 
Primary endpoint 
<10% FNR. 
Standardization of 
histopathological 
evaluation of post-
NST samples.  
Planned 
Trials 
University of  
Birmingham/  
Rea/ 
NOSTRA feasibility 
ER-negative or 
HER2-positive 
invasive breast 
cancer receiving 
NST/lesion size must 
be > 1 cm on 
ultrasound or node 
Ultrasound directed 
biopsy, minimum of 6 
150 Microcalcifications 
will not be targeted; 
no upper limit of 
size criteria 
FNR < 10% 
18 
 
positive 
NRG/BR005 
Basik and De Los 
Santos 
Operable focal or 
multifocal (T1-T3, 
stage II and IIIA 
invasive ductal 
carcinoma/ with no 
size criteria [all 
receptor 
phenotypes]), 
completed NST with 
a clinical complete 
response (by clinical 
examination) 
 
Patients must have 
achieved a complete 
or near complete 
radiologic tumor 
response on breast 
imaging with 
mammogram, 
ultrasound, and MRI  
 
Patients must be 
undergoing breast 
conserving therapy  
 
Patients must have a 
biopsy marker placed 
within the tumor bed 
with imaging 
confirmation 
(preferably 
mammogram but 
ultrasound or MRI is 
acceptable) of marker 
placement prior NST 
 
6 8-11G VACB, 
stereotactic  
 
175 Multicenter 
cooperative group 
study with tri-
modality imaging 
required 
NPV= 90% and 
FNR= 10% 
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Table 2.  Selective omission of breast cancer surgery following neoadjuvant systemic therapy: Essential questions and 
issues to resolve as the field advances  
 
 
General matters 
Which patients are most likely to achieve a pathologic complete response for both invasive and in situ disease? 
 
What specific systemic therapy agents are associated with maximal chances of a pCR (no residual invasive or in situ 
disease) in the breast and nodes? 
 
What is the best imaging modality or combination of imaging per breast cancer subtype to select patients for potential 
biopsy and elimination of surgery? 
 
What are the potential costs and cost savings of eliminating the need for surgery? 
 
What proportion of patients will be interested in clinical trial participation in which surgery will be avoided and what will be 
their willingness to participate in a single-arm versus randomization between surgery and no-surgery?  
 
What is the optimal oncologic endpoint and study design of a single arm “no surgery” or a randomized clinical trial of 
surgery vs. no-surgery trials in patients with biopsy confirmed pCR?  
 
Which are the optimal patients for consideration of eliminating surgery with respect to size and characteristics of the 
breast cancer, considering potential for under sampling and long term need for imaging follow-up? 
 
Can circulating tumor cells and/or circulating DNA or other serum markers be utilized in combination with imaging to better 
select patients with a pCR? 
 
 
 
Biopsy related 
 
20 
 
What is the acceptable FNR of a minimal invasive biopsy to demonstrate a pCR without influencing oncologic outcome if 
no surgery will be performed? 
 
What is the optimal method of minimal invasive biopsy: core cut vs. VACB in the post-NST setting (and is this influenced 
by sub-type)? 
 
What is the optimal number of core biopsies necessary to ensure the highest accuracy / lowest false-negative results (and 
is this influenced by sub-type)? 
 
What is the best method with respect to sectioning for evaluating core biopsies after NST to ensure the lowest chance of 
missing residual carcinoma?  
 
How much of the residual lesion(s) needs to be biopsied? 
 
Can residual microcalcifications that are no longer associated with malignancy on biopsy be left in situ and followed? 
 
What are objective and reliable diagnostic pathological signs of pCR of the breast in VAB specimen?  
 
How often will there be no histopathologic evidence of biopsy related changes when pCR occurs? 
 
Are there specific locations in the breast where optimal biopsy may not be feasible due to technical factors and how can 
this be overcome? 
 
Management of the axilla 
What is the best imaging tool; or combination of imaging tools for staging nodal disease prior to and following NST 
depending on sub-type?  
 
Can patients with initial documented nodal metastases participate safely in clinical trials of eliminating breast surgery? 
 
What is the correlation among exceptional responders with a pCR in the breast compared with final axillary nodal status? 
 
Does the axilla need to be treated with radiotherapy in cases with a pCR who do not undergo surgery? 
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Radiotherapy issues 
What is the optimal delivery method and fractionation for breast radiation when surgery is omitted (whole breast, 
hypofractionation, partial breast radiation)? 
 
Which nodal fields should be treated, if any? 
 
Should all patients receive a boost to the prior region of carcinoma? 
 
Is radiotherapy needed when there is complete pathologic response in the breast after NST? 
 
Follow-up 
What is the best imaging modality for following patients who do not undergo surgery for breast cancer and how often 
should it occur? 
 
What will the imaging characteristics of the breast and nodal regions among patients who do not have surgery and how 
often will biopsy be recommended based on imaging to rule out recurrence? 
 
What impact will eliminating surgery have on the quality of life, decisional comfort, and cosmetic outcome for patients? 
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Figure.  Clinical trial schema for the MD Anderson Cancer Center “Eliminating Breast Cancer Surgery in Exceptional 
Responders with Neoadjuvant Systemic Chemotherapy” currently accruing study. 
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